02 9487 9111
 

Sydney Adventist Hospital
« View pages

Clinical Specialties - Cancer

Bladder Cancer Clinical Trials

BCG-MMC 

Adding Mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: A randomized phase 3 trial "(BCG + MMC Trial)"

https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364165


FORT-1 - Recruiting

Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma

https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=6951&isClinicalTrial=True


KEYNOTE 676 - Pending

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676

https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=18065&isClinicalTrial=True

 

Back to Top

Sydney Adventist Hospital Clinical Specialties and Services